Acta neurologica Scandinavica · 2008
Paraneoplastic antibody during follow-up of a patient with anti-Ri-associated paraneoplastic neurological syndrome.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stich O, Rasiah C, Rauer S
Аннотация
BACKGROUND: The role of classical antineuronal antibody determinations to confirm the paraneoplastic aetiology of a neurological syndrome is well established. However, the value of antineuronal antibody estimation during follow-up of paraneoplastic neurological syndromes (PNS) is not known.
AIMS OF THE STUDY: Prospective analysis of antibody concentrations in follow-up serum samples from a patient with anti-Ri-associated PNS.
METHODS: Semiquantitative estimation of antibody concentrations with an ELISA using recombinant Ri antigen.
RESULTS: Semiquantitative estimation of circulating anti-Ri antibodies demonstrated a renewed increase in antibody levels preceding relapse of the cancer, as confirmed using F-fluorodeoxyglucose positron emission tomography (FDG-PET).
CONCLUSIONS: This is the first prospective report on serial anti-Ri antibody determinations. As a large increase in antineuronal antibody concentrations in follow-up serum samples preceded relapse of the cancer, paraneoplastic antineuronal antibodies may represent a marker for tumour activity in this case. These results warrant further multicentre studies to investigate the ability of serial quantification of classical antineuronal antibodies in monitoring PNS and in predicting relapse of cancers.
AIMS OF THE STUDY: Prospective analysis of antibody concentrations in follow-up serum samples from a patient with anti-Ri-associated PNS.
METHODS: Semiquantitative estimation of antibody concentrations with an ELISA using recombinant Ri antigen.
RESULTS: Semiquantitative estimation of circulating anti-Ri antibodies demonstrated a renewed increase in antibody levels preceding relapse of the cancer, as confirmed using F-fluorodeoxyglucose positron emission tomography (FDG-PET).
CONCLUSIONS: This is the first prospective report on serial anti-Ri antibody determinations. As a large increase in antineuronal antibody concentrations in follow-up serum samples preceded relapse of the cancer, paraneoplastic antineuronal antibodies may represent a marker for tumour activity in this case. These results warrant further multicentre studies to investigate the ability of serial quantification of classical antineuronal antibodies in monitoring PNS and in predicting relapse of cancers.
Предметные рубрики MeSH
AntibodiesAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCarcinomaCerebellar DiseasesDisease ProgressionEnzyme-Linked Immunosorbent AssayFatal OutcomeFemaleFollow-Up StudiesHumansImmunohistochemistryLymph NodesMediastinumNeoplasm Recurrence, LocalNerve Tissue ProteinsNeuro-Oncological Ventral AntigenParaneoplastic Syndromes, Nervous SystemPredictive Value of TestsProspective StudiesRNA-Binding ProteinsRadionuclide ImagingUp-Regulation